The MYSTIC trial assessed the efficacy of a durvalumab plus tremelimumab combination or durvalumab monotherapy compared to chemotherapy in advanced NSCLC patients with PD-L1 positive tumors (PDL-1 ≥ 25%). Here, CD274 is linked to non-small cell lung carcinoma.